CompletedPhase 1NCT01204476
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Studying Gastroenteric neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- James YaoM.D. Anderson Cancer Center
- Intervention
- Cixutumumab(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01204476 on ClinicalTrials.govOther trials for Gastroenteric neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07161882ALG-LungCancerRegistry (SAFRO2202)Société Algérienne de Formation et de Recherche en Oncologie
- ACTIVE NOT RECRUITINGPHASE2NCT03110978Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerM.D. Anderson Cancer Center